A lesson learned from COVID-19: The importance of non-inferiority (NI) trials for developing new antimicrobial agents before widespread need Access Viewpoint here: A lesson learned from COVID-19: The importance of non-inferiority (NI) trials for developing new antimicrobial agents before widespread need – by John Rex Author: John Rex Tags: Antimicrobial Viewpoint article, Regulatory
